Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Uveal Melanoma 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Medulloblastoma 1Laryngeal Diseases 1Glioma 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 12Nivolumab 6atezolizumab 3Ipilimumab 3tislelizumab 2spartalizumab 2durvalumab 2avelumab 2Etoposide 2ruxolitinib 1poly ICLC 1obinutuzumab 1naptumomab estafenatox 1milademetan 1epacadostat 1enzalutamide 1entinostat 1cemiplimab 1budigalimab 1bemcentinib 1Thrombopoietin 1Sirolimus 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Levoleucovorin 1Leucovorin 1LY2940680 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × LY2940680 × Other solid neoplasm × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡